These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 37742362)

  • 81. Development of Triamcinolone Acetonide-Loaded Nanostructured Lipid Carriers (NLCs) for Buccal Drug Delivery Using the Box-Behnken Design.
    Kraisit P; Sarisuta N
    Molecules; 2018 Apr; 23(4):. PubMed ID: 29690622
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Comparison of in vitro-activity of commonly used topical glucocorticoids on cytokine- and phospholipase inhibition.
    Juergens UR; Jäger F; Darlath W; Stöber M; Vetter H; Gillissen A
    Eur J Med Res; 2004 Aug; 9(8):383-90. PubMed ID: 15337628
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Development of Triamcinolone Acetonide-Loaded Microemulsion as a Prospective Ophthalmic Delivery System for Treatment of Uveitis: In Vitro and In Vivo Evaluation.
    Mahran A; Ismail S; Allam AA
    Pharmaceutics; 2021 Mar; 13(4):. PubMed ID: 33805986
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Triamcinolone acetonide-loaded lipid nanocapsules for ophthalmic applications.
    Formica ML; Ullio Gamboa GV; Tártara LI; Luna JD; Benoit JP; Palma SD
    Int J Pharm; 2020 Jan; 573():118795. PubMed ID: 31682964
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Intraocular concentration of triamcinolone acetonide after intravitreal injection in the rabbit eye.
    Kamppeter BA; Cej A; Jonas JB
    Ophthalmology; 2008 Aug; 115(8):1372-5. PubMed ID: 18355920
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Comparison of different techniques for purification of triamcinolone acetonide suspension for intravitreal use.
    García-Arumí J; Boixadera A; Giralt J; Martinez-Castillo V; Gomez-Ulla F; Corcostegui B; García-Arumí E
    Br J Ophthalmol; 2005 Sep; 89(9):1112-4. PubMed ID: 16113361
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Preparation and Characterization of Tacrolimus-Loaded SLNs in situ Gel for Ocular Drug Delivery for the Treatment of Immune Conjunctivitis.
    Sun K; Hu K
    Drug Des Devel Ther; 2021; 15():141-150. PubMed ID: 33469266
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Intravitreal triamcinolone acetonide: a change in a paradigm.
    Jonas JB
    Ophthalmic Res; 2006; 38(4):218-45. PubMed ID: 16763379
    [TBL] [Abstract][Full Text] [Related]  

  • 89. IS A DECREASED NITRIC OXIDE CONCENTRATION AFTER TRIAMCINOLONE ACETONIDE INTRAVITREAL INJECTION ONE OF THE REASONS FOR INTRAOCULAR PRESSURE RISE?
    Petrović N; Todorović D; Srećković S; Jovanović S; Petrović M; Stojadinović I; Šarenac Vulović T
    Acta Clin Croat; 2022 Dec; 61(4):620-628. PubMed ID: 37868182
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Distribution of fluorescein sodium and triamcinolone acetonide in the simulated liquefied and vitrectomized Vitreous Model with simulated eye movements.
    Stein S; Bogdahn M; Rosenbaum C; Weitschies W; Seidlitz A
    Eur J Pharm Sci; 2017 Nov; 109():233-243. PubMed ID: 28823853
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Effect of intranasal fluticasone propionate and triamcinolone acetonide on basal and dynamic measures of hypothalamic-pituitary-adrenal-axis activity in healthy volunteers.
    Bachert C; Lukat KF; Lange B
    Clin Exp Allergy; 2004 Jan; 34(1):85-90. PubMed ID: 14720267
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Safety and pharmacokinetics of a preservative-free triamcinolone acetonide formulation for intravitreal administration.
    Kim H; Csaky KG; Gravlin L; Yuan P; Lutz RJ; Bungay PM; Tansey G; DE Monasterio F; Potti GK; Grimes G; Robinson MR
    Retina; 2006; 26(5):523-30. PubMed ID: 16770258
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Intraocular availability of triamcinolone acetonide after intravitreal injection.
    Jonas JB
    Am J Ophthalmol; 2004 Mar; 137(3):560-2. PubMed ID: 15013884
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Design, Characterization, and Application of a pH-Triggered In Situ Gel for Ocular Delivery of Vinpocetine.
    Ma Q; Luo R; Zhang H; Dai M; Bai L; Fei Q; Lei F; He N
    AAPS PharmSciTech; 2020 Sep; 21(7):253. PubMed ID: 32888086
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Microfibrillar polymeric ocular inserts for triamcinolone acetonide delivery.
    Di Prima G; Licciardi M; Carfì Pavia F; Lo Monte AI; Cavallaro G; Giammona G
    Int J Pharm; 2019 Aug; 567():118459. PubMed ID: 31247275
    [TBL] [Abstract][Full Text] [Related]  

  • 96. A more efficient ocular delivery system of triamcinolone acetonide as eye drop to the posterior segment of the eye.
    Li J; Cheng T; Tian Q; Cheng Y; Zhao L; Zhang X; Qu Y
    Drug Deliv; 2019 Dec; 26(1):188-198. PubMed ID: 30835587
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Investigation of some commercially available spacer devices for the delivery of glucocorticoid steroids from a pMDI.
    Williams RO; Patel AM; Barron MK; Rogers TL
    Drug Dev Ind Pharm; 2001 May; 27(5):401-12. PubMed ID: 11448047
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Preparation, in vitro and in vivo Evaluation of Thermosensitive in situ Gel Loaded with Ibuprofen-Solid Lipid Nanoparticles for Rectal Delivery.
    Huang CH; Hu PY; Wu QY; Xia MY; Zhang WL; Lei ZQ; Li DX; Zhang GS; Feng JF
    Drug Des Devel Ther; 2022; 16():1407-1431. PubMed ID: 35586185
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Application of hydroxyapatite nanoparticles in development of an enhanced formulation for delivering sustained release of triamcinolone acetonide.
    Koocheki S; Madaeni SS; Niroomandi P
    Int J Nanomedicine; 2011; 6():825-33. PubMed ID: 21589650
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Controlled non-invasive iontophoretic delivery of triamcinolone acetonide amino acid ester prodrugs into the posterior segment of the eye.
    Santer V; Chen Y; Kalia YN
    Eur J Pharm Biopharm; 2018 Nov; 132():157-167. PubMed ID: 30266666
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.